Evidence map›Paper›PMID 42314092›Full record

Observational studyJCO precision oncology2026

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic

Christine M Lovly, Christina Baik, Misako Nagasaka, Tejas Patil, Sonia S Maruti, Stephen Stanhope, Neslihan A Kaya, Stephan Herbertz, Beth Nordstrom, Kathryn Evans and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christine M LovlyDepartment of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0002-3641-6361
Christina BaikFred Hutchinson Cancer Center, University of Washington, Seattle, WA.
Misako NagasakaDivision of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange County, CA.ORCID 0000-0001-5308-615X
Tejas PatilDepartment of Medicine, University of Colorado Cancer Center, Aurora, CO.ORCID 0000-0003-4389-1010
Sonia S MarutiBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
Stephen StanhopeBoehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
Neslihan A KayaBoehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
Stephan HerbertzBoehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
Beth NordstromThermo Fisher Scientific, Waltham, MA.
Kathryn EvansThermo Fisher Scientific, Waltham, MA.ORCID 0000-0001-7675-6750
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-8554-1185

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis observational study assessed the real-world characteristics, treatments, and outcomes of US patients with

methodsDeidentified data were extracted for patients with advanced/metastatic NSCLC from the Flatiron Health-Foundation Medicine NSCLC Clinico-Genomic Database. Patients with oncogenic

resultsOverall, 559/14,768 (3.8%) patients had

conclusionNSCLC patients with oncogenic TKD

Indexed as

Carcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsMutationAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID42314092
PMCPMC13290063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.